Researchers have found links to multiple new benefits – and new side effects – in a study of weight-loss drugs such as ...

About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...

Research has found that GLP-1 receptors, found in medications like Wegovy and Monjaro, may offer health benefits beyond the ...

Two weeks into the job, it’s clear that newly elected State Treasurer Brad Briner won’t shy away from taking action, even if ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity Research. Current market leaders include Novo Nordisk NVO and Eli Lilly LLY with ...

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...

A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like Ozempic and Wegovy, provide significant neurological and behavioral health ...

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

Millions of obese Americans have achieved successful weight loss through use of glucagon-like peptide-1 agonists (GLP-1), a game-changing class of obesity medications. Results are often dramatic, but ...

More than one-third of websites selling their own versions implied the products were the same as the FDA-approved drugs.